Impact Factor
3.54
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.88
1,274 total citations
h5-index
32
h5 depth signal
Cited share
73.7%
334 of 453
Total citations
1,274
Citation footprint
Metric signal
2.72
External metric anchor
Self-citation
2.6%
33 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
503
Italy
278
Germany
260
United Kingdom
149
France
148
Citing Fields of Research
Hematology
1,330
Lymphomas
634
Immunology
193
Oncology
108
Clinical Laboratory Science
68
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
7,147
Articles tracked across the journal lifetime
Indexed publication set
453
334 cited publications
Last 12 months
293
24.4 publications/month
Open access share
47.1%
138 OA publications in the last year
Leading citing country
United States
503 citing publications
Leading citing field
Hematology
1,330 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v38n1,Jan. 1987-
v38n1,Jan. 1987-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Lymphomas
Broad Categories
Hematology
Lymphomas
MeSH Descriptors
Hematology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1111/ejh.70338
Open DOI
Partial Red Cell Exchange in the Secondary Prevention of Stroke in Sickle Cell Disease: A Prospective Study
Introduction: Stroke is a severe complication associated with sickle cell disease (SCD). The risk of recurrence is extremely high. The present study aimed to assess the clinical and biological efficacy of Partial Red Cell Exchange (PRE) ...
02
DOI 10.1111/ejh.70340
Open DOI
Chimeric Antigen Receptor T‐Cell Therapy in T Cell/Histiocyte‐Rich Large B‐Cell Lymphoma: A Systematic Review and Meta‐Analysis
T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL) is a rare subtype of B‐cell non‐Hodgkin lymphoma with an aggressive clinical course and poor prognosis in the case of relapsed or refractory ( r / r ) disease. Recently, anti‐CD19 ch...
03
DOI 10.1111/ejh.70336
Open DOI
Association Between the Time of Day of Post‐Transplant Cyclophosphamide Administration and Haemorrhagic Cystitis After Allogeneic Haematopoietic Stem Cell Transplantation
Objective: To evaluate the impact of the time‐of‐day (daytime vs. nighttime) of the infusion of post‐transplantation cyclophosphamide (PTCy) on the occurrence of haemorrhagic cystitis (HC) in adult patients undergoing allogeneic haematop...
04
DOI 10.1111/ejh.70339
Open DOI
Elevated Risks for Depression and Anxiety Following Diagnosis of Multiple Myeloma
Background: Patients with multiple myeloma (MM) may be particularly vulnerable to depression and anxiety following diagnosis due to high disease burden, treatment‐related side effects, and the incurable nature of the disease. Methods: In...
05
06
07
DOI 10.1111/ejh.70099
Open DOI
Issue Information
08
DOI 10.1111/ejh.70328
Open DOI
BCMA ‐Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management
Background: B‐cell maturation antigen (BCMA), a plasma cell‐restricted member of the tumor necrosis factor receptor superfamily, has emerged as the premier immunotherapeutic target in Multiple Myeloma (MM). Methods: We performed a compre...
09
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.